Skip to content

Investors

Investor Relations

Atara Biotherapeutics, Inc. is a biotechnology company developing T-cell immunotherapies for patients with severe and life-threatening diseases who have been underserved by scientific innovation, with a focus on cancer and autoimmune and infectious diseases.  Atara's "Off-the-Shelf" allogeneic T-cell immunotherapy platform harnesses the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses.  Atara's most advanced product candidate, ATA129, for cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disease (EBV-PTLD) and other EBV positive solid tumors is expected to enter Phase 3 clinical studies in 2017.  The company's clinical stage pipeline also includes cytotoxic T-cells (CTL) targeting Wilms Tumor 1 (WT1), or ATA520, and Cytomegalovirus (CMV), or ATA230.  Atara's next generation T-cell immunotherapy for autoimmune disease is an EBV-specific CTL product candidate, or ATA188, that selectively targets specific antigens of EBV believed to be important for the potential treatment of multiple sclerosis (MS).
NASDAQ: ATRA
14.25
- 0.15 (-1.04%)
Day High: 14.35
Day Low:  14.00
Volume:    168,327
4:00 PM ET on May 26, 2017

Delayed at least 20 minutes.